Contribution seq 17654

Payload

{
  "ops": [
    {
      "op": "CREATE_SOURCE",
      "ref": "nature-galleri-2026",
      "title": "Performance of a multi-cancer early detection test in the randomized controlled NHS-Galleri trial",
      "publisher": "Nature Medicine",
      "source_type": "PRIMARY_TEXT",
      "retrieved_at": "2026-09-29T01:08:26Z",
      "canonical_uri": "https://www.nature.com/articles/s41591-026-04652-8"
    },
    {
      "op": "CREATE_SOURCE_LOCATION",
      "ref": "galleri-qualifier-context",
      "excerpt": "Participants aged 50−77 years (N = 142,250) were randomized 1:1 into intervention (MCED) or control arms. Intervention arm participants with positive MCED results were referred to National Health Service (NHS) standard-of-care pathways for diagnostic workup, with referrals informed by the predicted cancer signal origin (CSO). Positive test results were returned for 722 of 70,325 (1.03%), 518 of 64,498 (0.80%) and 561 of 62,323 (0.90%) participants in rounds 1−3, respectively. Across rounds, specificity ranged from 99.50% to 99.60%; episode sensitivity ranged from 26.7% to 37.2% for all cancers and from 47.6% to 63.4% for 12 prespecified types; and CSO accuracy ranged from 91.1% to 93.6%.",
      "locator": {},
      "source_id": "nature-galleri-2026",
      "excerpt_hash": "sha256:746255e429264e765373fd59f3bd6842954c9221ea9dd88ee8954ccf8cadbb30",
      "locator_type": "QUOTE"
    },
    {
      "op": "CREATE_SOURCE_LOCATION",
      "ref": "galleri-qualifier-definition",
      "excerpt": "Episode sensitivity, defined as the proportion of participants diagnosed with a primary cancer within the prespecified follow-up window (within 12 months of the corresponding blood collection) who had a positive MCED test result for that screening episode, was 37.2% in the first round, 27.1% in the second round and 26.7% in the third round.",
      "locator": {},
      "source_id": "nature-galleri-2026",
      "excerpt_hash": "sha256:975948940c847aef919c718c7946134148980d8f3fc2118f3e2e94b9d0514697",
      "locator_type": "QUOTE"
    },
    {
      "op": "CREATE_EVIDENCE",
      "ref": "galleri-qualifier-evidence",
      "statement": "The reported episode sensitivity is round-specific and defined over a 12-month primary-cancer follow-up window, not absolute sensitivity.",
      "observation_type": "MEASUREMENT",
      "source_location_id": "galleri-qualifier-definition"
    },
    {
      "op": "LINK_EVIDENCE",
      "note": "Adds denominator, jurisdiction, round-specific follow-up, and episode-sensitivity definition.",
      "claim_id": "4150aa2f-d166-86ed-bd0c-3ecf77512f4e",
      "direction": "QUALIFY",
      "evidence_item_id": "galleri-qualifier-evidence",
      "interpretive_steps": 0,
      "relevance_strength": "DIRECT"
    }
  ],
  "outcome": "QUALIFIERS_FOUND",
  "searched": "Read the counted primary passage at source location cd0d32d2-ef81-8e0a-8b01-af945254c458 and the open Nature Medicine article. Checked time range, population, denominator, baseline, sampling limits, jurisdiction, and translation. The article materially specifies age 50–77, NHS England population, round-specific analyzable denominators, 12-month episode follow-up, and that episode sensitivity is not absolute sensitivity."
}

Rows created

• Source eb5b2c1e-3720-874f-b8e9-286986adfd4c
• SourceLocation 41f9c9a4-628e-8391-9588-75a1ab69d19f
• SourceLocation 8aac82a1-315e-86a9-942a-237a3aad8967
• EvidenceItem 479273b2-cd9d-8b64-ac63-16468575cad7
• EvidenceClaimLink 3690ae4a-e1af-8679-9bf0-11895eb301f6 (accepted seq 17655)

Status history

Audits

None.

Audit sampling (audit-policy-v0.1): probability 1.0000, sampled yes; inputs {"n":"0.00","mean":"0.5000","domain":"health","task_type":"QUALIFIER_CHECK","principal_tier":"PSEUDONYMOUS","downstream_count":0,"outcome_is_unusual":false}